Loading...
Keywords
Last Name
Institution

Vivekanand Yadav, PhD

TitleDoctoral Research Faculty
InstitutionChildren's Mercy Kansas City
DepartmentHematology/Oncology/BMT
Address2401 Gillham Rd
Kansas City MO 64108
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionUniversity of Missouri-Kansas City
    DepartmentPediatrics

    TitleAssistant Professor
    InstitutionUniversity of Kansas Medical Center
    DepartmentCancer Biology


    Collapse Biography 
    Collapse education and training
    University of Pune, IndiaPh.D01/2012Biotechnology
    Karmanos Cancer Institute, Wayne State University, Detroit, USAPostDoctoral06/2013Cancer Biology
    University of Michigan, Ann Arbor, USAPostDoctoral06/2018Neuro-Oncology
    University of Michigan, Ann Arbor, USAResearch Investigator05/2022Pediatric Neuro-Oncology
    Collapse awards and honors
    2021 - 2023New Investigator Award , Chad Tough Defeat DIPG Foundation
    2020Faculty award for basic science research, Department of Pediatrics, University of Michigan

    Collapse Overview 

    Collapse Research 
    Collapse research overview
    Diffuse midline gliomas (DMGs) are the most aggressive pediatric high-grade gliomas and are the leading cause of cancer-related deaths in children. At present, there are no effective therapies for DMGs tumors, and over 90% of patients die within 1.5 years of diagnosis. In his lab, Dr. Yadav is leading efforts to understand genetic and epigenetic dependencies and signaling pathways that arise as a consequence of the H3K27M mutation in DMG. His lab performs pre-clinical studies using a novel in utero electroporation (IUE)-derived genetically engineered mouse model to identify promising candidates that can be targeted as therapy for the treatment of DMG.

    1-Identifying genomic and epigenetic drivers of pediatric brain tumors with specific genetic alterations (H3K27M or H3G34R/V) using next-generation sequencing and a novel in utero electroporation (IUE) genetically engineered mouse model.

    2-Developing more effective treatments by dissecting the resistance mechanisms of pediatric brain tumors using genome-wide CRISPR-based genetic screens.
    Collapse research activities and funding
    AWD018127     (Vivekanand Yadav)Aug 1, 2021 - Feb 29, 2024
    The ChadTough Defeat DIPG Foundation for the 'New Investigator Award
    Epigenetically activated ID1 is a key transcriptional regulator of DIPG Invasion and is targetable with cannabidiol
         (Vivekanand Yadav)Oct 1, 2022 - Sep 30, 2023
    Tom Keaveny Award
    Upregulation of prenatal pontine ID1 signaling in DIPG,

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, Filbin M, Franson A, Galban S, Garcia Moure M, Garton H, Gowda P, Marques JG, Hawkins C, Heath A, Hulleman E, Ji S, Jones C, Kilburn L, Kline C, Koldobskiy MA, Lim D, Lowenstein PR, Lu QR, Lum J, Mack S, Magge S, Marini B, Martin D, Marupudi N, Messinger D, Mody R, Morgan M, Mota M, Muraszko K, Mueller S, Natarajan SK, Nazarian J, Niculcea M, Nuechterlein N, Okada H, Opipari V, Pai MP, Pal S, Peterson E, Phoenix T, Prensner JR, Pun M, Raju GP, Reitman ZJ, Resnick A, Rogawski D, Saratsis A, Sbergio SG, Souweidane M, Stafford JM, Tzaridis T, Venkataraman S, Vittorio O, Wadden J, Wahl D, Wechsler-Reya RJ, Yadav VN, Zhang X, Zhang Q, Venneti S. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. 2024 Jan 08; 42(1):1-5. PMID: 38039965.
      View in: PubMed
    2. Ausejo-Mauleon I, Labiano S, de la Nava D, Laspidea V, Zalacain M, Marrod?n L, Garc?a-Moure M, Gonz?lez-Huarriz M, Herv?s-Corpi?n I, Dhandapani L, Vicent S, Collantes M, Pe?uelas I, Becher OJ, Filbin MG, Jiang L, Labelle J, de Biagi-Junior CAO, Nazarian J, Laternser S, Phoenix TN, van der Lugt J, Kranendonk M, Hoogendijk R, Mueller S, De Andrea C, Anderson AC, Guruceaga E, Koschmann C, Yadav VN, G?llego P?rez-Larraya J, Pati?o-Garc?a A, Pastor F, Alonso MM. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell. 2023 11 13; 41(11):1911-1926.e8. PMID: 37802053.
      View in: PubMed
    3. Messinger D, Harris MK, Cummings JR, Thomas C, Yang T, Sweha SR, Woo R, Siddaway R, Burkert M, Stallard S, Qin T, Mullan B, Siada R, Ravindran R, Niculcea M, Dowling AR, Bradin J, Ginn KF, Gener MAH, Dorris K, Vitanza NA, Schmidt SV, Spitzer J, Li J, Filbin MG, Cao X, Castro MG, Lowenstein PR, Mody R, Chinnaiyan A, Desprez PY, McAllister S, Dun MD, Hawkins C, Waszak SM, Venneti S, Koschmann C, Yadav VN. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro Oncol. 2023 01 05; 25(1):54-67. PMID: 35605606.
      View in: PubMed
    4. Schwark K, Messinger D, Cummings JR, Bradin J, Kawakibi A, Babila CM, Lyons S, Ji S, Cartaxo RT, Kong S, Cantor E, Koschmann C, Yadav VN. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine. Front Oncol. 2022; 12:922928. PMID: 35978801.
      View in: PubMed
    5. Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Nand Yadav V, Ravindran R, Bruzek AK, Wadden J, John V, May Babila C, Cummings JR, Rahman Kawakibi A, Ji S, Ramos J, Paul A, Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venneti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner SL, Koschmann C. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022 08 01; 24(8):1366-1374. PMID: 35137228.
      View in: PubMed
    6. Qin T, Mullan B, Ravindran R, Messinger D, Siada R, Cummings JR, Harris M, Muruganand A, Pyaram K, Miklja Z, Reiber M, Garcia T, Tran D, Danussi C, Brosnan-Cashman J, Pratt D, Zhao X, Rehemtulla A, Sartor MA, Venneti S, Meeker AK, Huse JT, Morgan MA, Lowenstein PR, Castro MG, Yadav VN, Koschmann C. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Rep. 2022 01 11; 38(2):110216. PMID: 35021084.
      View in: PubMed
    7. Sweha SR, Chung C, Natarajan SK, Panwalkar P, Pun M, Ghali A, Bayliss J, Pratt D, Shankar A, Ravikumar V, Rao A, Cieslik M, Wilder-Romans K, Scott AJ, Wahl DR, Jessa S, Kleinman CL, Jabado N, Mackay A, Jones C, Martinez D, Santi M, Judkins AR, Yadav VN, Qin T, Phoenix TN, Koschmann CJ, Baker SJ, Chinnaiyan AM, Venneti S. Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. Sci Transl Med. 2021 Oct 13; 13(615):eabf7860. PMID: 34644147.
      View in: PubMed
    8. Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, Robertson PL, Garton HJ, Wahl DR, Parmar H, Sarkaria JN, Kline C, Mueller S, Nicolaides T, Glasser C, Leary SE, Venneti S, Kumar-Sinha C, Chinnaiyan AM, Mody R, Pai MP, Phoenix TN, Marini BL, Koschmann C. Everolimus improves the efficacy of dasatinib in PDGFRa-driven glioma. J Clin Invest. 2020 10 01; 130(10):5313-5325. PMID: 32603316.
      View in: PubMed
    9. Chung C, Sweha SR, Pratt D, Tamrazi B, Panwalkar P, Banda A, Bayliss J, Hawes D, Yang F, Lee HJ, Shan M, Cieslik M, Qin T, Werner CK, Wahl DR, Lyssiotis CA, Bian Z, Shotwell JB, Yadav VN, Koschmann C, Chinnaiyan AM, Bl?ml S, Judkins AR, Venneti S. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer Cell. 2020 09 14; 38(3):334-349.e9. PMID: 32795401.
      View in: PubMed
    10. Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Correction to: Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. Curr Oncol Rep. 2020 Apr 16; 22(5):47. PMID: 32297022.
      View in: PubMed
    11. Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. Curr Oncol Rep. 2020 02 06; 22(2):19. PMID: 32030483.
      View in: PubMed
    12. Yadav VN, Altshuler D, Kadiyala P, Zamler D, Comba A, Appelman H, Dunn P, Koschmann C, Castro MG, L?wenstein PR. Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. Neuro Oncol. 2018 09 03; 20(10):1356-1367. PMID: 29660022.
      View in: PubMed
    13. Pyaram K, Yadav VN. Advances in NKT cell Immunotherapy for Glioblastoma. J Cancer Sci Ther. 2018; 10(6). PMID: 30147849.
      View in: PubMed
    14. Kumar J, Yadav VN, Phulera S, Kamble A, Gautam AK, Panwar HS, Sahu A. Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I. J Virol. 2017 10 01; 91(19). PMID: 28724763.
      View in: PubMed
    15. Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav VN, Koschmann C, Asad AS, Lowenstein PR, Castro MG. Single vs. combination immunotherapeutic strategies for glioma. Expert Opin Biol Ther. 2017 05; 17(5):543-554. PMID: 28286975.
      View in: PubMed
    16. Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget. 2016 12 13; 7(50):83701-83719. PMID: 27863376.
      View in: PubMed
    17. Calinescu AA, Yadav VN, Carballo E, Kadiyala P, Tran D, Zamler DB, Doherty R, Srikanth M, Lowenstein PR, Castro MG. Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism. Clin Cancer Res. 2017 Mar 01; 23(5):1250-1262. PMID: 27542769.
      View in: PubMed
    18. Yadav VN, Castro MG, Lowenstein PR. Neurotropic Viral Infections, Carol Shoshkes Reiss. Viral Gene Therapy for Central Nervous System Diseases. 2016; 519-544.
    19. Kathania M, Zeng M, Yadav VN, Moghaddam SJ, Yang B, Venuprasad K. Ndfip1 regulates itch ligase activity and airway inflammation via UbcH7. J Immunol. 2015 Mar 01; 194(5):2160-7. PMID: 25632008.
      View in: PubMed
    20. Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. 2014 Sep 15; 74(18):5079-90. PMID: 25038230.
      View in: PubMed
    21. Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia. 2014 Jul; 16(7):543-61. PMID: 25117977.
      View in: PubMed
    22. Lowenstein PR, Yadav VN, Chockley P, Castro M. There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther. 2014 Feb; 22(2):246-247. PMID: 24487564.
      View in: PubMed
    23. Yadav VN, Pyaram K, Ahmad M, Sahu A. Species selectivity in poxviral complement regulators is dictated by the charge reversal in the central complement control protein modules. J Immunol. 2012 Aug 01; 189(3):1431-9. PMID: 22732591.
      View in: PubMed
    24. Yadav VN, Hansen T, G?rbitz CH. 1,1'-(4,4'-Bipiperidine-1,1'-di-yl)bis-(2,2,2-trifluoro-ethanone). Acta Crystallogr Sect E Struct Rep Online. 2011 Jul 01; 67(Pt 7):o1691. PMID: 21837088.
      View in: PubMed
    25. Pyaram K, Kieslich CA, Yadav VN, Morikis D, Sahu A. Influence of electrostatics on the complement regulatory functions of Kaposica, the complement inhibitor of Kaposi's sarcoma-associated herpesvirus. J Immunol. 2010 Feb 15; 184(4):1956-67. PMID: 20089702.
      View in: PubMed
    26. Sreejith RK, Yadav VN, Varshney NK, Berwal SK, Suresh CG, Gaikwad SM, Pal JK. Conformational characterization of human eukaryotic initiation factor 2alpha: a single tryptophan protein. Biochem Biophys Res Commun. 2009 Dec 11; 390(2):273-9. PMID: 19800319.
      View in: PubMed
    27. Singh AK, Yadav VN, Pyaram K, Mullick J, Sahu A. Mapping of functional domains in herpesvirus saimiri complement control protein homolog: complement control protein domain 2 is the smallest structural unit displaying cofactor and decay-accelerating activities. J Virol. 2009 Oct; 83(19):10299-304. PMID: 19640995.
      View in: PubMed
    28. Yadav VN, Pyaram K, Mullick J, Sahu A. Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J Virol. 2008 Apr; 82(7):3283-94. PMID: 18216095.
      View in: PubMed
    29. Mullick J, Singh AK, Panse Y, Yadav V, Bernet J, Sahu A. Identification of functional domains in kaposica, the complement control protein homolog of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). J Virol. 2005 May; 79(9):5850-6. PMID: 15827200.
      View in: PubMed
    Yadav's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (173) concept(s)
    _
    Co-Authors Expand Description
    See all (1) people
    _
    Similar People Expand Description
    See all (60) people
    _